3-Chloro-4-(3-Fluorobenzyloxy)aniline CAS 202197-26-0 Lapatinib Intermediate Purity >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 3-Chloro-4-(3-Fluorobenzyloxy)aniline (CAS: 202197-26-0) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Lapatinib Intermediates, Please contact: alvin@ruifuchem.com
Chemical Name | 3-Chloro-4-(3-Fluorobenzyloxy)aniline |
Synonyms | 3-Chloro-4-[(3-Fluorophenyl)methoxy]aniline; 4-(3-Fluorobenzyloxy)-3-Chlorobenzenamine; Lapatinib Intermediate B |
Stock Status | In Stock, Commercial Production |
CAS Number | 202197-26-0 |
Molecular Formula | C13H11ClFNO |
Molecular Weight | 251.69 g/mol |
Melting Point | 78.0 to 82.0℃ |
Density | 1.306±0.06 g/cm3 |
COA & MSDS | Available |
Sample | Available |
Origin | Shanghai, China |
Brand | Ruifu Chemical |
Items | Inspection Standards | Results |
Appearance | Brown to Black Powder | Complies |
Melting Point | 78.0 to 82.0℃ | 80.7℃ |
Loss on Drying | <1.00% | Complies |
Residue on Ignition | <0.50% | Complies |
Related Impurities by HPLC | <2.00% | 0.64% |
Purity / Analysis Method | >98.0% (HPLC) | 99.36% |
1H NMR Spectrum | Consistent with Structure | Complies |
Conclusion | The product has been tested and complies with the given specifications | |
Application | Intermediate of Lapatinib / Lapatinib Ditosylate Monohydrate |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
UN IDs 3077
HS Code 2921420090
Hazard Class 9
Packing Group III
3-Chloro-4-(3-Fluorobenzyloxy)aniline (CAS: 202197-26-0) is an intermediate in the synthesis of Lapatinib / Lapatinib Ditosylate Monohydrate.
Lapatinib is a drug targeting breast cancer developed by British GlaxoSmithKline Co. Human ErbB receptors belong to the type I tyrosine kinase (TK) receptor family, including ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The ErbB-1 (EGFR) and ErbB-2 (HER-2) receptors are often overexpressed or otherwise altered in cancer patients. Human epidermal growth factor receptor 2 (ErbB-2, HER-2) is known to be a human oncogene closely related with breast cancer. Its high expression in breast cancer often predicts lymph node metastasis and poor tumor differentiation, with poor prognosis. HER-2 is one of the target molecules for breast cancer-specific therapy. Lapatinib can act simultaneously on both Her-1 Her-2. The biological effects of this method inhibiting the proliferation and growth of tumor cells are much larger than only acting on one target. The combination of Lapatinib with Capecitabine is used to treat patients with advanced or metastatic breast cancer with overexpression of human epidermal receptor2, already treated with anthracyclines, paclitaxel, and trastuzumab. Clinical trials have shown that Lapatinib also effectively treats HER2-type cancer patients with Herceptin resistance.